Ticker >

Eris Lifesciences share price

Eris Lifesciences Ltd.

NSE: ERIS BSE: 540596 SECTOR: Pharmaceuticals & Drugs  68k   280   31

907.10
+9.95 (1.11%)
BSE: Today, 04:01 PM

Price Summary

Today's High

₹ 920

Today's Low

₹ 886.65

52 Week High

₹ 971

52 Week Low

₹ 609.45

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationFair
The stock’s market price justifies its intrinsic value.
EfficiencyExcellent
The company knows very well the utilization of its assets.
FinancialsAverage
The company could improve upon its asset employment.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

12340.87 Cr.

Enterprise Value

12610.09 Cr.

No. of Shares

13.6 Cr.

P/E

35.46

P/B

4.97

Face Value

₹ 1

Div. Yield

0.81 %

Book Value (TTM)

₹  182.56

CASH

47.65 Cr.

DEBT

316.87 Cr.

Promoter Holding

54.9 %

EPS (TTM)

₹  25.58

Sales Growth

9.46%

ROE

19.25 %

ROCE

20.54%

Profit Growth

-4.6 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Brands

These are the brands of Eris Lifesciences Ltd.

GLIMISAVE ERITEL OLMIN TENDIA RENERVE REMYLIN RABONIK TAYO LNBLOC CYBLEX ATORSAVE ROSIFLEX CREVAST RARICAP SERLIFT

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year9.46%
3 Year9.26%
5 Year11.84%

Profit Growth

1 Year-4.6%
3 Year10.97%
5 Year6.27%

ROE%

1 Year19.25%
3 Year22.54%
5 Year23.92%

ROCE %

1 Year20.54%
3 Year24.69%
5 Year24.96%

Debt/Equity

0.1428

Price to Cash Flow

38.29

Interest Cover Ratio

21.8539449190969

CFO/PAT (5 Yr. Avg.)

0.900284081126683

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Mar 2024 54.9 18.51
Dec 2023 54.9 10.95
Sep 2023 54.91 10.95
Jun 2023 52.86 11.37
Mar 2023 52.86 0
Investors List
* Figures given above are % of equity capital

 Strengths

  • Company has been maintaining healthy ROE of 22.5381233136716% over the past 3 years.
  • Company has been maintaining healthy ROCE of 24.6943245765985% over the past 3 years.
  • Company has a healthy Interest coverage ratio of 21.8539449190969.
  • The Company has been maintaining an effective average operating margins of 36.8380725640768% in the last 5 years.
  • The company has an efficient Cash Conversion Cycle of -70.2766780638751 days.

 Limitations

  • The company has shown a poor revenue growth of 9.26042416143698% for the Past 3 years.
  • Promoter pledging has increased from 10.9481254715886% to 18.51% in 1 quarter.
  • Tax rate is low at 8.9041017506998.

Quarterly Result (All Figures in Cr.)

PARTICULARS Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
Net Sales 332.01 314.58 411.29 409.71 324.41
Total Expenditure 205.62 203.09 255.79 265.22 249.98
Operating Profit 126.39 111.49 155.5 144.49 74.43
Other Income 3.48 4.26 4.03 6.98 3.43
Interest 3.14 2.96 6.84 6.55 15.14
Depreciation 16.5 17.28 20.16 25 28.08
Exceptional Items 0 0 0 0 0
Profit Before Tax 110.23 95.51 132.52 119.92 34.64
Tax 10.85 7.67 21.78 2.11 2.99
Profit After Tax 99.38 87.84 110.74 117.81 31.66
Adjusted EPS (Rs) 7.31 6.46 8.14 8.66 2.33

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Net Sales 896.54 1020.23 1108.83 1215.73 1330.73
Total Expenditure 562.77 665.28 691.36 731.68 825.47
Operating Profit 333.77 354.96 417.47 484.06 505.26
Other Income 32.5 15.49 10 28.99 17.26
Interest 22.9 1.97 0.94 3.05 20.95
Depreciation 31.59 44.88 37.64 51.46 64.66
Exceptional Items 0 0 0 0 0
Profit Before Tax 311.78 323.59 388.89 458.54 436.91
Tax 26.4 32.32 38.29 41.35 38.9
Net Profit 285.38 291.27 350.61 417.19 398.01
Adjusted EPS (Rs.) 20.75 21.45 25.82 30.69 29.27

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Equity and Liabilities
Share Capital 13.75 13.58 13.58 13.59 13.6
Total Reserves 1142.26 1286.12 1561.89 1904.96 2208.29
Borrowings 0 0 0 0 209.47
Other N/C liabilities -114.05 -130.18 -161.82 -170.49 -205.26
Current liabilities 360.47 203.06 212.42 249.79 361.73
Total Liabilities 1402.42 1372.59 1626.08 1997.86 2587.83
Assets
Net Block 483.85 600.64 584.32 642 897.81
Capital WIP 0.75 0 0 0 0
Intangible WIP 1.98 4.37 1.56 2.98 0.34
Investments 274.36 246.03 480.97 678.18 966.52
Loans & Advances 16 15.44 25.36 11.14 85.95
Other N/C Assets 5.88 2.88 42.27 0 7.18
Current Assets 619.6 503.22 491.6 663.56 630.03
Total Assets 1402.42 1372.59 1626.08 1997.86 2587.83
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Profit from operations 311.78 323.59 388.89 458.54 436.91
Adjustment 24.57 39.36 36.11 31.04 73.7
Changes in Assets & Liabilities -50.18 -47.37 38.44 -37.26 -110.5
Tax Paid -69.86 -50.34 -68.04 -82.9 -77.79
Operating Cash Flow 216.31 265.25 395.41 369.41 322.33
Investing Cash Flow 2.08 126.74 -347.86 -267.64 -513.3
Financing Cash Flow -220.74 -333.52 -81.13 -88.42 193.75
Net Cash Flow -2.34 58.47 -33.58 13.36 2.78

Corporate Actions

Investors Details

PARTICULARS Mar 2023% Jun 2023% Sep 2023% Dec 2023% Mar 2024%
promoters 52.86 52.86 54.91 54.90 54.90
amit indubhushan bakshi - - - - 42.88
inderjeet singh negi 4.37 4.37 4.37 4.37 4.37
kaushal kamleshkumar shah... 3.29 3.29 3.29 3.29 3.29
rajendrakumar rambhai pat... 4.37 4.37 4.37 4.37 4.37
amit indubhusan bakshi 40.84 40.84 42.89 42.88 -
PARTICULARS Mar 2023% Jun 2023% Sep 2023% Dec 2023% Mar 2024%
investors 47.14 47.14 45.09 45.10 45.10
bhikhalal chimanlal shah 4.32 4.31 4.30 4.30 2.76
emerald investments limit... 7.58 7.58 7.58 7.58 7.27
franklin india smaller co... 1.26 1.26 1.47 1.47 1.46
hdfc small cap fund - - 4.57 5.39 6.60
hetal rasiklal shah 2.68 2.68 2.62 2.58 2.58
llp - 0.02 0.02 0.03 0.04
rakesh shah 11.53 11.53 4.88 4.88 4.88
uti flexi cap fund 5.33 5.92 4.74 3.94 4.14
kuwait investment authori... 1.47 1.47 1.10 1.03 -
plutus wealth management ... - - 1.10 1.10 -

Annual Reports

Ratings & Research Reports

Company Presentations

Company News

Eris Lifesciences gets nod to raise up to Rs 1250 crore via NCDs 21 May 2024, 6:14PM Eris Lifesciences informs about update on board meeting17 May 2024, 3:45PM Eris Lifesciences planning to raise funds17 May 2024, 12:44PM Eris Lifesciences informs about analyst meet 21 Mar 2024, 4:50PM Eris Lifesciences acquires Biocon Biologics’ India branded formulation business15 Mar 2024, 10:59AM Eris Lifesciences informs about outcome of board meeting 14 Mar 2024, 4:56PM Eris Lifesciences informs about transcript of investor call20 Feb 2024, 3:35PM Eris Lifesciences acquires 51% stake in Swiss Parenterals16 Feb 2024, 11:53AM Eris Lifesciences - Quaterly Results13 Feb 2024, 3:35PM Eris Lifesciences - Quaterly Results13 Feb 2024, 3:35PM Eris Lifesciences - Quaterly Results13 Feb 2024, 3:35PM Eris Lifesciences informs about disclosure 9 Nov 2023, 10:39AM Eris Lifesciences - Quaterly Results8 Nov 2023, 2:22PM Eris Lifesciences - Quaterly Results8 Nov 2023, 2:22PM Eris Lifesciences - Quaterly Results8 Nov 2023, 2:22PM Eris Lifesciences informs about confirmation certificate12 Oct 2023, 4:56PM Eris Lifesciences informs about analyst meet20 Sep 2023, 2:19PM Eris Lifesciences informs about analyst meet 6 Sep 2023, 10:48AM Eris Lifesciences to avail rupee term loan facility of Rs 120.82 crore from Citi Bank N.A.22 Aug 2023, 11:18AM Eris Lifesciences - Quaterly Results7 Aug 2023, 1:00PM Eris Lifesciences - Quaterly Results7 Aug 2023, 1:00PM Eris Lifesciences - Quaterly Results7 Aug 2023, 1:00PM Eris Lifesciences informs about analyst meet7 Jul 2023, 2:08PM Eris Lifesciences informs about investors meeting 5 Jul 2023, 4:56PM Eris Lifesciences submits analyst meet intimation29 May 2023, 12:21PM Eris Lifesciences reports 23% fall in Q4 consolidated net profit 17 May 2023, 4:43PM Eris Lifesciences - Quaterly Results17 May 2023, 2:36PM Eris Lifesciences - Quaterly Results17 May 2023, 2:36PM Eris Lifesciences - Quaterly Results17 May 2023, 2:36PM Eris Lifesciences informs about analyst meet10 Apr 2023, 12:06PM Eris Lifesciences informs about analyst meet 4 Apr 2023, 10:05AM Eris Lifesciences informs about analyst meet 3 Apr 2023, 12:35PM Eris Lifesciences informs about analyst meet 20 Mar 2023, 12:39PM Eris Lifesciences planning to acquire nine dermatology brands from Dr Reddy's Laboratories 16 Mar 2023, 2:50PM Eris Lifesciences informs about analyst meet 15 Feb 2023, 11:58AM Eris Lifesciences reports marginal fall in Q3 consolidated net profit18 Jan 2023, 12:59PM Eris Lifesciences - Quaterly Results17 Jan 2023, 5:33PM Eris Lifesciences - Quaterly Results17 Jan 2023, 5:33PM Eris Lifesciences - Quaterly Results17 Jan 2023, 5:33PM Eris Lifesciences informs about analyst meet intimation4 Jan 2023, 12:49PM Eris Lifesciences informs about analyst meet 9 Nov 2022, 12:50PM Eris Lifesciences - Quaterly Results20 Oct 2022, 12:43PM Eris Lifesciences - Quaterly Results20 Oct 2022, 12:43PM Eris Lifesciences - Quaterly Results20 Oct 2022, 12:43PM Eris Lifesciences informs about disclosure24 Sep 2022, 4:22PM Eris Lifesciences informs about institutional investor meetings19 Sep 2022, 10:26AM Eris Lifesciences informs about investor meet3 Sep 2022, 3:27PM Eris Lifesciences - Quaterly Results5 Aug 2022, 12:55PM Eris Lifesciences - Quaterly Results5 Aug 2022, 12:55PM Eris Lifesciences - Quaterly Results5 Aug 2022, 12:55PM

Eris Lifesciences Stock Price Analysis and Quick Research Report. Is Eris Lifesciences an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Eris Lifesciences and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Eris Lifesciences cash from the operating activity was Rs 322.328 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Eris Lifesciences has a Debt to Equity ratio of 0.1428 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Eris Lifesciences , the EPS growth was -4.64066832400943 % which is bad for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Eris Lifesciences has OPM of 37.9684006838378 % which is a good sign for profitability.
     
  • ROE: Eris Lifesciences have a average ROE of 19.2472540571961 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Eris Lifesciences is Rs 907.95. One can use valuation calculators of ticker to know if Eris Lifesciences share price is undervalued or overvalued.
Last Updated on:
Brief about Eris Lifesciences

Eris Lifesciences Ltd. Financials: Check Share price, Balance Sheet, Annual report, and Quarterly Results for company analysis

Eris Lifesciences Ltd.'s stock analysis page provides long-term investors with the necessary tools and resources to make informed investment decisions. These tools and resources include share price, balance sheet, annual report, dividend, quarterly result, stock price, price chart, news, concall, transcripts, investor presentations, promoters, and shareholders analysis. Our website also offers pre-built screening tools to analyze the stock's performance compared to its peers and premium feature tools such as DCF Analysis, BVPS Analysis, Earnings multiple approach, and DuPont analysis. Annual reports and quarterly results are provided as downloadable documents for in-depth analysis.

Eris Lifesciences Ltd. Share Price Analysis:


When assessing long-term investment opportunities, analyzing Eris Lifesciences Ltd.'s share price is a critical factor. Our stock analysis page provides historical share price charts, which are a valuable resource for users to monitor the company's performance over time. Further analysis of this data can then be conducted using our pre-built screening tools to help investors analyze Eris Lifesciences Ltd.'s share price performance better. The analysis includes tracking the company's stock prices regularly, charting trends and assessing the future performance potential. A stock's share price is determined by a range of factors such as market sentiment, financial performance, and general economic conditions. 

Eris Lifesciences Ltd. Balance Sheet Analysis:


Eris Lifesciences Ltd.'s balance sheet is a crucial indicator of the company's financial strength and stability. A thorough analysis of the balance sheet is essential for investors to understand the company's financial health and assess growth potential accurately. Our website offers access to Eris Lifesciences Ltd.'s balance sheet as a downloadable document, which users can use to perform an in-depth analysis for long-term investment decisions. Further analysis can be conducted using our premium feature tools such as DCF Analysis, BVPS Analysis, Earnings multiple approaches, and DuPont analysis.

Eris Lifesciences Ltd. Annual Report Analysis:


Eris Lifesciences Ltd.'s annual report provides critical information for long-term investors regarding the company's strategic initiatives and financial performance. Understanding the annual report is essential for long-term investors since it offers insights into the company's future growth trajectory. Our website offers access to Eris Lifesciences Ltd.'s annual report as a downloadable document, which investors can use for an in-depth analysis of the company's performance. Our pre-built screening tools can assist investors in analyzing the company's performance compared to its peers, which can allow for better decision-making.

Eris Lifesciences Ltd. Dividend Analysis:


Dividend payout policies are an essential factor for long-term investors considering the viability of investing in any company's stock. Eris Lifesciences Ltd.'s dividend payout trends are a factor that investors should consider when assessing the stock's potential. Ticker features insights into Eris Lifesciences Ltd.'s dividend payout trends, which can assist long-term investors in analyzing the stock's viability as a long-term investment option.

Eris Lifesciences Ltd. Quarterly Results Analysis:


Eris Lifesciences Ltd.'s quarterly results hold critical information regarding the company's financial performance, including revenue, profits, and losses. The data from these reports can be used by long-term investors to assess the company's growth potential. Our website provides a downloadable copy of Eris Lifesciences Ltd.'s quarterly results, which investors can use to make informed analysis of the company's financial health for long-term investment decisions. Further analysis of this data can be conducted using our premium feature tools such as DCF Analysis, BVPS Analysis, Earnings multiple approach, and DuPont analysis.

Eris Lifesciences Ltd. Stock Price Analysis:


Monitoring Eris Lifesciences Ltd.'s stock prices is critical to analyzing the stock's overall performance. Our stock analysis page features current stock price updates which investors can access to assess market trends and potential investment opportunities. Ticker's pre-built screening tools can help investors analyze the stock's performance compared to its peers and help investors make informed investment decisions for the long term. Our website provides pre-built screening tools to help investors analyze stock price and performance.

Eris Lifesciences Ltd. Price Chart Analysis:


A visual representation of Eris Lifesciences Ltd.'s share price trends over a period is an essential tool for long-term investors. It helps investors track the company's performance over time and make informed investment decisions. Ticker provides investors with a price chart to visualize Eris Lifesciences Ltd.'s share price trends over a specific period. Our pre-built screening tools can assist investors in analyzing the company's performance compared to its peers, which can allow for better decision-making.

Eris Lifesciences Ltd. News Analysis:


Keeping up with Eris Lifesciences Ltd.'s recent news and developments is crucial for investors. Our website provides timely news articles related to Eris Lifesciences Ltd. to provide investors with up-to-date insights into the stock's performance. The news section of our website offers reliable information on important events, regulatory changes, and other factors that may impact the stock's performance. Our pre-built screening tools can also provide investors with information about the company's global and local news.

Eris Lifesciences Ltd. Concall Transcripts Analysis:


Eris Lifesciences Ltd.'s concall transcripts provide investors with insights into the company's future guidance and outlook. Our website provides access to these critical documents, allowing long-term investors to stay informed on the company's financial health and future growth. Further analysis of this data can be conducted using our premium feature tools such as DCF Analysis, BVPS Analysis, Earnings multiple approach, and DuPont analysis.

Eris Lifesciences Ltd. Investor Presentations Analysis:


Eris Lifesciences Ltd. prepares investor presentations to provide investors with detailed information on the company's operations and performance. These presentations serve as essential resources for long-term investors to study the company's strategic initiatives, offering necessary insights that can impact the stock's value. Our website offers access to these presentations, which investors can download for an in-depth analysis. Our premium feature tools can assist investors in performing an in-depth analysis of the presented data.

Eris Lifesciences Ltd. Promoters and Shareholders Analysis:


Assessing the viability of investing in Eris Lifesciences Ltd.'s stock requires considering the company's promoters and shareholders. Our stock analysis page features essential information about the company's promoters and other shareholders. Long-term investors must consider these elements before making informed investment decisions. Further analysis of the company's shareholding patterns can be conducted using our pre-built screening tools.

Read More
X